APCCC 2024: Are Some Patients with Biochemical Recurrence (After Radiotherapy And/or Radical Prostatectomy) Candidates for Androgen Receptor Antagonist Monotherapy and How to Manage the Systemic Therapy?
APCCC 2024, prostate cancer, prostate cancer biochemical recurrence, Androgen Receptor Antagonist Monotherapy, EMBARK trial, enzalutamide, bicalutamide, leuprolide acetate, Gynecomastia after prostate cancer treatment, antineoplastic therapy, tamoxifen, anastrozole.